NRx Pharmaceuticals To Proceed With Two New Drug Applications In 2024; NRX-101 Returned To Company For Filing
Portfolio Pulse from Benzinga Newsdesk
NRx Pharmaceuticals plans to file two New Drug Applications (NDAs) in 2024 for NRX-101 and NRX-100, targeting bipolar depression, akathisia, and suicidal depression. These drugs have received Breakthrough Therapy and Fast Track Designations, respectively. Potential revenue from these drugs could exceed $150 per NRXP share. Additionally, HOPE Therapeutics is progressing towards a public listing.
June 28, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NRx Pharmaceuticals plans to file NDAs for NRX-101 and NRX-100 in 2024, targeting bipolar depression and suicidal depression. These drugs have received Breakthrough Therapy and Fast Track Designations, respectively. Potential revenue from these drugs could exceed $150 per NRXP share. Additionally, HOPE Therapeutics is progressing towards a public listing.
The filing of NDAs for NRX-101 and NRX-100, both of which have received significant designations, indicates strong potential for approval and subsequent revenue generation. The potential revenue exceeding $150 per share is a significant positive indicator for investors. Additionally, the progress towards a public listing for HOPE Therapeutics adds another layer of potential value.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100